Synthesis of O-[2-[18F]fluoro-3-(2-nitro-1H-imidazole-1-yl) propyl]tyrosine ([18F]FNT]) as a new class of tracer for imaging hypoxia

Journal of Radioanalytical and Nuclear Chemistry

Volumn 292, Issue 3, 2012, Pages 1025-1033

  Malik, Noeen ^a   Shen, Bin ^c   Lin, Xian ^a   Löffler, Dirk ^b   Solbach, Christoph ^a   Voelter, Wolfgang ^e   Reischl, Gerald ^d   MacHulla, Hans Jürgen ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b ETH ZURICH   (Switzerland)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Hypoxia imaging; P tyrosine with 2 nitroimidazole; Radiofluorinations

Indexed keywords

AMINO ACID; METHYL 2 (BENZYLOXYCARBONYL) 3 [4 3 [(2 NITRO 1H IMIDAZOLE 1 YL) 2 (TOSYLOXY)PROPOXY]PHENYL]PROPANOATE; METHYL 2 (BENZYLOXYCARBONYL) 3 [4[2 [FLUORINE 18]FLUORO 3 (2 NITRO 1H IMIDAZOLE 1 YL)PROPOXY]]PHENYLPROPANOATE; O [2 [FLUORINE 18]FLUORO 3 (2 NITRO 1H IMIDAZOLE 1 YL)PROPYL]TYROSINE; PROPIONIC ACID DERIVATIVE; TRACER; UNCLASSIFIED DRUG; AMINO ACID TRANSPORTER; CHEMICAL COMPOUND; METHYL 2 (BENZYLOXYCARBONYL) 3 [4 [2 FLUORO 3 (2 NITRO 1H IMIDAZOLE 1 YL)PROPOXY]PHENYL]PROPANOATE; O [2 FLUORO 3 (2 NITRO 1H IMIDAZOLE 1 YL)PROPYL]TYROSINE F 18;

AMINO ACID SUBSTITUTION; ARTICLE; DIAGNOSTIC IMAGING; DRUG PURITY; DRUG STRUCTURE; HYPOXIA; ISOTOPE LABELING; NUCLEOPHILICITY; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RADIOSYNTHESIS; STRUCTURE ANALYSIS; SUBSTITUTION REACTION; SYNTHESIS; TEMPERATURE MEASUREMENT; DRUG SYNTHESIS; DRUG TRANSPORT; RADIOISOTOPE DECAY;

EID: 84863434652     PISSN: 02365731     EISSN: 15882780     Source Type: Journal    
DOI: 10.1007/s10967-012-1683-4     Document Type: Article

References (13)

1. Machulla H-J (1999) Imaging of hypoxia: tracer developments. Kluwer Academic Publishers, 33: p-15.
2. Grierson JR, Link JM, Mathis CA, Rasey JS, Krohn KAJ (1989) Nucl Med 30(3):343-350.
3. Piert M, Machulla H-J, Becker G, Stahlschmidt A, Patt M, Aldinger P, Dissmann PD, Fischer H, Bares R, Becker HD, Lauchart W (1999) Eur J Nucl Med 26(2):95-109.
4. Piert M, Machulla H-J, Becker G, Aldinger P, Winter E, Bares R (2000) Nucl Med Biol 27(8):693-700.
5. Reischl G, Ehrlichmann W, Bieg C, Solbach C, Kumar P, Wiebe L, Machulla H-J (2005) Appl Radiat Isot 62(6):701-897.
6. Reischl G, Sabbah A, Machulla H-J (2007) J Nucl Med 48(Supplement-2): 325P.
7. Krohn KA, Link JM, Mason RPJ (2008) Nucl Med 49(Supplement-2):129S-148S.
8. Jain-Vakkalagadda B, Dey S, Pal D, Mitra AK (2003) Investig Ophthalmol Vis Sci 44(7):2919-2927.
9. Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H (2002) Mol Pharmacol 61:729-737.
10. Langen KJ, Roosen N, Coenen HH, Kuikka JT, Kuwert T, Herzog H, Stöcklin G, Feinendegen LE (1991) J Nucl Med 32(6):1225-1229.
11. Boado RJ, Li JY, Tsukamoto H, Pardridge WM (2003) J Neurochem 85(4):1037-1042.
12. Soh H, Wasa M, Fukuzawa M (2007) J Pediatr Surg 42(4): 608-612.
13. Malik N, Machulla H-J, Solbach C, Winter G, Reske SN, Zlatopolskiy B (2011) Appl Radiat Isot 69(7):1014-1018